The Library
Quality of Vitamin K antagonist control and 1-Year outcomes in patients with atrial fibrillation : a global perspective from the GARFIELD-AF registry
Tools
Tools
Tools
(2016) Quality of Vitamin K antagonist control and 1-Year outcomes in patients with atrial fibrillation : a global perspective from the GARFIELD-AF registry. PLoS One, 11 (10). e0164076. doi:10.1371/journal.pone.0164076 ISSN 1932-6203.
|
PDF
WRAP-quality-Vitamin-K-antagonist-control-Fitzmaurice-2017.PDF - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1120Kb) | Preview |
Official URL: http://dx.doi.org/10.1371/journal.pone.0164076
Abstract
Aims:
Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) of 2.0–3.0 for stroke prevention in atrial fibrillation (AF). We analysed the time in this therapeutic range (TTR) of VKA-treated patients with newly diagnosed AF in the ongoing, global, observational registry GARFIELD-AF. Taking TTR as a measure of the quality of patient management, we analysed its relationship with 1-year outcomes, including stroke/systemic embolism (SE), major bleeding, and all-cause mortality.
Methods and Results:
TTR was calculated for 9934 patients using 136,082 INR measurements during 1-year follow-up. The mean TTR was 55.0%; values were similar for different VKAs. 5851 (58.9%) patients had TTR<65%; 4083 (41.1%) TTR≥65%. The proportion of patients with TTR≥65% varied from 16.7% in Asia to 49.4% in Europe. There was a 2.6-fold increase in the risk of stroke/SE, 1.5-fold increase in the risk of major bleeding, and 2.4-fold increase in the risk of all-cause mortality with TTR<65% versus ≥65% after adjusting for potential confounders. The population attributable fraction, i.e. the proportion of events attributable to suboptimal anticoagulation among VKA users, was 47.7% for stroke/SE, 16.7% for major bleeding, and 45.4% for all-cause mortality. In patients with TTR<65%, the risk of first stroke/SE was highest in the first 4 months and decreased thereafter (test for trend, p = 0.021). In these patients, the risk of first major bleed declined during follow-up (p = 0.005), whereas in patients with TTR≥65%, the risk increased over time (p = 0.027).
Conclusion:
A large proportion of patients with AF had poor VKA control and these patients had higher risks of stroke/SE, major bleeding, and all-cause mortality. Our data suggest that there is room for improvement of VKA control in routine clinical practice and that this could substantially reduce adverse outcomes.
| Item Type: | Journal Article | ||||||
|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine | ||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||
| Library of Congress Subject Headings (LCSH): | Cerebrovascular disease -- Prevention, Atrial fibrillation, Vitamin K | ||||||
| Journal or Publication Title: | PLoS One | ||||||
| Publisher: | Public Library of Science | ||||||
| ISSN: | 1932-6203 | ||||||
| Official Date: | 28 September 2016 | ||||||
| Dates: |
|
||||||
| Volume: | 11 | ||||||
| Number: | 10 | ||||||
| Article Number: | e0164076 | ||||||
| DOI: | 10.1371/journal.pone.0164076 | ||||||
| Status: | Peer Reviewed | ||||||
| Publication Status: | Published | ||||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||||
| Date of first compliant deposit: | 24 November 2017 | ||||||
| Date of first compliant Open Access: | 24 November 2017 | ||||||
| Funder: | bayer | ||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
